EXCEED THE SPACE PROVIDED. HIV combined with either latent or active tuberculosis poses devastating consequences both in the U.S. and overseas. With no new drug class approved for tuberculosis since 1967 and with the growing )roblem of multidrug-resistant tuberculosis (MDRTB), the development of new agents to treat active or latent TB in the setting of HIV is a high priority. Modern drug discovery is a pipeline, which initiates with the identification of an appropriate target and culminates in pre-clinical evaluation of drug candidates and clinical trials. In this application we propose basic research on the identification of drug targets plus the development of several novel approaches to )reclinical antimicrobial characterization in vitro and in vivo. A central tenet of the first aim of the application is that the best drug targets are those which are strictly essential for the organism. Through the use of random transposon mutagenesis, precise characterization of 1425 mutants by DNA sequencing, and a Monte Carle biostatistical model of essential genes, we have identified 878 non-essential genes of M. tuberculosis and 22 genes with probabilities of being essential ranging from 93-75%. Several of the likely essential genes have known inhibitors which we have found to be active against M. tuberculosis in vitro. We propose to extend this work to identify and characterize additional essential gene targets. Secondly towards advancing the later-stages of the drug development pipeline, we have developed the use of diffusion bioreactors with flow rate control for assessing critical )harmacodynamic parameters of drugs active against mycobacteria. In a related vein we have developed traditional and novel animal models which may predict drug activity against human latent tuberculosis infection (LTBI). We propose to extend the use of these tools, and to evaluate novel preventive therapy regimens for LTBI in the setting of exposure to drug-resistant TB such as might occur in areas with high MDRTB prevalence or in a bioterrorism attack. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043846-08
Application #
6838738
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Laughon, Barbara E
Project Start
1998-08-01
Project End
2007-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
8
Fiscal Year
2005
Total Cost
$408,750
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lun, Shichun; Miranda, David; Kubler, Andre et al. (2014) Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to ?-lactams. MBio 5:e01767-14
Olaleye, Omonike; Raghunand, Tirumalai R; Bhat, Shridhar et al. (2011) Characterization of clioquinol and analogues as novel inhibitors of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis (Edinb) 91 Suppl 1:S61-5
Olaleye, Omonike; Raghunand, Tirumalai R; Bhat, Shridhar et al. (2010) Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets. Chem Biol 17:86-97
Parrish, Nicole M; Ko, Chiew G; Dick, James D (2009) Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro. Tuberculosis (Edinb) 89:325-7
Ahmad, Zahoor; Klinkenberg, Lee G; Pinn, Michael L et al. (2009) Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 200:1136-43
Be, Nicholas A; Lamichhane, Gyanu; Grosset, Jacques et al. (2008) Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system. J Infect Dis 198:1520-8
Klinkenberg, Lee G; Sutherland, Lesley A; Bishai, William R et al. (2008) Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 198:275-83
Lee, Jong-Hee; Karakousis, Petros C; Bishai, William R (2008) Roles of SigB and SigF in the Mycobacterium tuberculosis sigma factor network. J Bacteriol 190:699-707
Nuermberger, Eric; Tyagi, Sandeep; Tasneen, Rokeya et al. (2008) Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-4
Abdul-Majid, Khairul-Bariah; Ly, Lan H; Converse, Paul J et al. (2008) Altered cellular infiltration and cytokine levels during early Mycobacterium tuberculosis sigC mutant infection are associated with late-stage disease attenuation and milder immunopathology in mice. BMC Microbiol 8:151

Showing the most recent 10 out of 50 publications